Overview

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
Phase:
Phase 3
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Silodosin